OUR NEW PROFILE IS: (NASDAQ: BTCY)
BTCY has shown triple-digit, quarter-over-quarter, year-over-year growth since day 1 (10 consecutive quarters)
Biotricity Reported Record Quarterly and Annual Revenue for Fiscal 2021
BTCY has been rated by Maxim Group, Noble Financial, and Northland Securities in the past 120 days, with price targets of $6 & $7
We profiled this one back on October 8 where it opened at 3.10. Less than a month later it hit 4.99 for a 75% move. It is still holding strong at 4.27 right now.
We wanted to update you regarding one of our recent profiles.
We showed you this company last month as a company we should be looking at over the long term.
Turn your attention back to Nasdaq: BTCY.
BTCY was on the OTC just a few months back. It has recently completed it’s up-listing to the Nasdaq, an accomplishment that many talk about and very few are actually able to execute on.
We took look at this one back in early October when it was trading just above $3. It made a strong 75% move from those levels over the next month and is still holding strong now sitting above $4.25.
Since we last looked at this one we have seen the company come out with several key news announcements, including its tenth consecutive quarter of triple-digit year-over-year revenue growth.
Biotricity Expands Distribution of New Bioheart Device on Amazon.com
New Heart Monitoring Solution Delivers Personalized Heart Health Insights Directly to Your Smartphone
Now Easy to Buy and Use: No Prescription Needed for Advanced Heart and Lifestyle Solution.
REDWOOD CITY, CA / ACCESSWIRE / December 28, 2021 /Biotricity Inc.(NASDAQ:BTCY) a modern medical technology company delivering innovative, remote biometric monitoring solutions, today announced it has expanded the distribution of its new Bioheart heart monitor system, a direct-to-consumer device that offers the same continuous heart monitoring technology used by physicians, on Amazon.com.
Last month the company launched commercial sales of its Bioheart device. To improve availability and expand outreach, Biotricity has now listed it for purchase on Amazon.com at: Bioheart on Amazon for $199 with a special introductory price of $149 for a limited time. You can view the Bioheart heart monitor in use here.
“We are aiming to transform the cardiac health marketplace and believe the Bioheart system will play an important role in that endeavor,” said Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO, “The Bioheart device is an important component of our full spectrum, ‘virtual cardiac clinic’ of mobile cardiac care and lifestyle solutions. It will be fully integrated with a growing number of cardiology practices through our cloud-based ‘Biosphere’ ecosystem that we plan to fully roll out in 2022, allowing physicians to get a more holistic view of a patient’s health.
“The ability to offer Bioheart on Amazon expands the availability for the public to easily access the benefits of this exciting technology,” Dr. Waqaas added.
The launch of Bioheart opens a new market and revenue stream for Biotricity while expanding the company’s total addressable market by $1.24B. Heart conditions are intermittent, requiring long-term data collection for effective insights and lifestyle management. With continuous monitoring, Bioheart reinvents personal heart management with retrospective snapshots and long-term data collection.
Introducing a groundbreaking new capability, users can collect data for hours, days, weeks, months, and even years! They can create snapshots of rhythm data by reviewing past data and marking it for personal records. These are first-of-its-kind features that will help individuals look back at their data for a richer understanding of their lifestyle impact and heart health.
Bioheart features include:
- Built-in dry contacts for data collection
- Advanced data collection – three different heart views
- 24/7 continuous rhythm recording
- 48-hour battery life
- Personalized analytics
- Bluetooth connected
With the Bioheart smartphone app, users can:
- View electrical heart rhythm live on the app
- View data on advanced heart metrics such as electrical heart rhythm, heart rate and heart rate variability
- View historical heart rate ranges
- Create a heart rhythm diary and save snapshots of heart activity
- Easily create retrospective snapshots, a first-of-its kind capability
- Easily export and share heart data with a physician
Bioheart incorporates the Company’s proprietary advanced heart technology, combined with powerful analytics and continuous rhythm recording, to help individuals understand and improve their heart health. Individuals can track their heart statistics 24/7 with three different views of the heart, which can be streamed live on the Bioheart smartphone app. Bioheart is the most accurate heart monitor available without a prescription.
Biotricity Delivers Bioheart, A Groundbreaking Consumer Heart Monitor
Continuous monitoring device with advanced features and analytics to deliver personalized insights directly to the smartphone
REDWOOD CITY, Calif., November 10, 2021–(BUSINESS WIRE)–Biotricity, Inc.(NASDAQ:BTCY), a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions, today announced the availability of Bioheart, a direct-to-consumer heart monitor that offers the same continuous heart monitoring technology used by physicians. Showcased in prototype form at CES 2020, Bioheart has shipped to preorder customers and is now available for purchase at www.bioheart.com.
The launch of Bioheart opens a new market and revenue stream for Biotricity while expanding the company’s total addressable market by $1.24B, the global heart rate monitoring market. “Launching Bioheart and expanding into this new market is an important step for Biotricity and our ultimate goal of building a complete cardiac ecosystem to service individuals throughout their heart health journey,” said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity.
Heart conditions are intermittent, requiring long term data collection for effective insights. With continuous monitoring, Bioheart reinvents personal heart management with retrospective snapshots. Introducing a groundbreaking new capability, users can create snapshots of rhythm data by reviewing past data and marking it for personal records. This is a first-of-its-kind feature that will help individuals look back at their data for a richer understanding of their lifestyle impact and heart health.
Bioheart incorporates the Company’s proprietary advanced heart technology, combined with powerful analytics and continuous rhythm monitoring, to help individuals understand and improve their heart health. It provides 24/7 electrical heart rhythm monitoring and recording with three different views of the heart, which can be streamed live on the Bioheart smartphone app. Bioheart is the most accurate heart monitor available without a prescription.
“Bioheart combines unparalleled accuracy in a heart monitoring device with continuous data, advanced heart health insights, and powerful features tailored to individuals at risk for heart disease or who want precise data for performance tracking, optimization and preventative cardiac wellness,” said Dr. Al-Siddiq. “Bioheart furthers Biotricity’s mission of developing revolutionary healthcare solutions that help engage and empower individuals to take control of their health, starting with the deadliest chronic disease and one of healthcare’s largest cost drivers: cardiac disease.”
Heart condition signs are typically intermittent, and most heart monitoring devices only capture short periods of heart activity. These devices have limited capabilities and do not provide individuals with the heart data or tools needed to support preventative care and effective lifestyle improvements. With Bioheart’s continuous monitoring and long-term data collection approach, users can analyze heart data from previous months, well after the initial recording, to understand changes and long-term trends.
“Bioheart has the potential to make an immediate, life-changing impact for those who use it,” added Dr. Al-Siddiq. “As a direct manufacturer, we’re thrilled to have been able to accelerate our market delivery to the general market in less than a year, ahead of schedule and in time for the busy holiday gifting season.”
BTCY is Targeting a Growing and Underserved Market with the Bioflux.
The company’s first and primary solution, Bioflux, addresses the growing and underserved Mobile Cardiac Telemetry (MCT) market.
Bioflux is a high-precision, single-unit MCT device providing real-time monitoring and transmission of ECG information from ambulatory patients. This entire system is a complete solution for remote cardiac monitoring that merges seamlessly with physicians’ existing platforms and workflows to better detect, diagnose, and monitor.
For medical practitioners, this solution looks to be technologically superior and more financially attractive too. Clinicians designed the Bioflux online portal for clinicians. After all, the prime features of the product were built after speaking with numerous healthcare professionals and seeing what their most requested features were.
They track over 100 billion heartbeats a year, monitored in real-time by their certified cardiac technicians with unmatched reporting capabilities.
- Company reports tenth consecutive quarter of triple-digit year-over-year revenue growth
- Strongest balance sheet since inception
REDWOOD CITY, CA / ACCESSWIRE / November 4, 2021 /Biotricity Inc.(NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced financial results for its 2022 fiscal year’s second quarter ended September 30, 2021.
In its fiscal second quarter, Biotricity reported its tenth consecutive quarter of triple-digit year-over-year revenue growth despite COVID-related headwinds.
Q2-FY22 financial and operating highlights include:
- Revenue of $1.81 million, an increase of 143% year-over-year and sequentially slightly above the $1.76 million reported in the immediately preceding quarter reflecting the Company’s seasonally soft quarters ended September 30.
- Net loss of $11 million or $0.256 per share. Net loss was negatively impacted by $5.46 million in one-time expenses related to its up-listing onto Nasdaq; consisting of listing transactional costs of $516,503, conversion-related expenses on convertible notes of $4.6 million as well as IR and legal expenses of $351,370. Absent that $5.46 million in one-time expenses, the net loss would have been $5.2 million, or $0.128 per share, which compares favorably sequentially with the $5.6 million loss, or $0.156 loss per share, in the preceding quarter ended March 31, 2021.
- Ended the September 30, 2021 quarter with the Company’s strongest balance sheet ever with $11.7 million in cash.
- Gross margin of 62%, as the business continues to scale well with revenue growth accelerating relative to operating expenses.
- Introduction of the Company’s personal medical device kit, Biokit, a bundled home-use set comprised of three FDA cleared, remote wireless devices for integration into the Biotricity ecosystem platform. It is the next step in the evolution of the Bioflux solution as a complete solution for remote cardiac monitoring.
“This was a historic quarter with our recent listing on the Nasdaq, in which we strengthened our balance sheet, and introduced our plans for Biokit and its commercial launch in the first quarter of calendar 2022,” stated Dr. Waqaas Al-Siddiq, CEO and founder of Biotricity. “We have disclosed several other state-of-the-art remote cardiac monitoring devices and software apps in our development pipeline – all of which are planned for commercialization in 2022, pending FDA clearance where required.
“Although this quarter is seasonally soft due to the August period, sales were also impacted by hurricanes and COVID-related clinic closures in the southern US,” added the Company’s Chief Financial Officer, John Ayanoglou. “We expect to recapture much of the past quarter’s delayed revenue in subsequent months when clinics open and reschedule patient appointments.”
“As important as our strong progress was in the quarter just ended,” Dr. Waqaas added, “we see 2022 as our true breakout year as we anticipate launching several new products, each of which integrate synergistically into our Biosphere platform. This is how we will achieve our vision of providing a complete cardiac solution — to dramatically reduce medical costs and improve patient outcomes.”
“Our goal is to penetrate and monetize a patient population that we have already touched with our cardiac diagnostics – to monitor and ensure they are provided with superior chronic care throughout their remaining life. Doing this within a recurring revenue business model is something we believe our investors will value.”
(sourced from MarketBeat)
Biotricity (OTCMKTS:BTCY) Analyst Ratings Frequently Asked Questions
WHAT IS BIOTRICITY’S CONSENSUS RATING AND PRICE TARGET?
According to the issued ratings of 4 analysts in the last year, the consensus rating for Biotricity stock is Buy based on the current 4 buy ratings for BTCY. The average twelve-month price target for Biotricity is $6.75 with a high price target of $7.00 and a low price target of $6.00. Learn more on BTCY’s analyst rating history
DO WALL STREET ANALYSTS LIKE BIOTRICITY MORE THAN ITS COMPETITORS?
Analysts like Biotricity stock more than the stock of other Medical companies. The consensus rating score for Biotricity is 3.00 while the average consensus rating score for medical companies is 2.72. Learn more on how BTCY compares to other companies
DO MARKETBEAT USERS LIKE BIOTRICITY MORE THAN ITS COMPETITORS?
MarketBeat users like Biotricity stock less than the stock of other Medical companies. 66.32% of MarketBeat users gave Biotricity an outperform vote while medical companies recieve an average of 67.44% outperform votes by MarketBeat users.
DOES BIOTRICITY’S STOCK PRICE HAVE MUCH UPSIDE?
According to analysts, Biotricity’s stock has a predicted upside of 87.63% based on their 12-month price targets.
WHAT ANALYSTS COVER BIOTRICITY?
Biotricity, a Leader in Remote Cardiac Health Monitoring Solutions, Issues Company Roadmap in 2021 Shareholder Letter
The Company believes that it is “well-positioned for 2022.”
Letter highlights milestones, products roadmap, growth strategy and 2022 goals
REDWOOD CITY, CA / ACCESSWIRE / December 7, 2021 / Biotricity, Inc.(NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, has released its December 2021 CEO Shareholder Letter, which discusses recent Company milestones achieved including its financial performance, commercialization of its new Biokit, and other state-of-the-art remote cardiac monitoring devices and software apps in development.
Highlights from the shareholder letter include:
- Recent uplisting to Nasdaq that the Company believes will help further attract a larger pool of sophisticated institutional investors, and a potential increase in liquidity and visibility
- Commercialization of the personal medical 3-devices kit, Biokit, for integration into the Biotricity ecosystem
- Record quarterly revenue of $1.81 million for its 2022 fiscal year’s second quarter ended September 30, 2021, up 143% year-over-year – its tenth consecutive quarter of triple-digit year-over-year growth
- The product roadmap for Bioflux®, Biotres, Biocare® Telemed, Biokit, and Bioheart
- The Company’s 2022 goals including launching new state-of-the-art cardiac monitoring solutions and software services.
Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity commented, “We had a historic second quarter that saw revenue increase 143% YoY, the strengthening of our balance sheet, and uplisting to Nasdaq which has boosted our exposure to investors worldwide. We’ve made great strides in each vertical we targeted over the year and are well-positioned to continue the execution of our overall growth plan for 2022. We seek to take telemedicine to a new, next-generation level of cost-effectiveness as well as disrupt the cardiac care landscape by reducing patient care costs with improved patient outcomes.”
The Biotricity December 2021 Shareholder Letter can be viewed at https://www.biotricity.com/wp-content/uploads/2016/09/Biotricity_Letter-To-Shareholders-Dec21.pdf
Company Expects New Personal Medical Device Kit to be available to customer by early 2022
REDWOOD CITY, CA / ACCESSWIRE / September 14, 2021 /Biotricity Inc.(NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has developed a personal medical device kit, Biokit, a bundled home-use set comprised of a digital thermometer, a pulse oximeter, and a blood pressure cuff. All three devices are FDA cleared, wireless capable and integrate into the Biotricity ecosystem, a platform for interconnectivity. This is the next step in the evolution of the Bioflux solution, where other available tools are fully integrated to create a complete solution for remote cardiac monitoring.
You can see that BTCY has recently made a strong move in the past 3 months and now we are seeing activity pick up and interest start to come into this one as the recent up-listing to the Nasdaq will attract a whole new class of investors who wouldn’t take a look at this one while it was listed on the OTC.
Capital infusion to finance inventory and annual recurring revenue subscriptions replaces expiring debt with more favorable terms5-year term deal strengthens balance sheet, positions company for multiple new product launches in 2022 REDWOOD CITY, CA / ACCESSWIRE / December 27, 2021 /Biotricity Inc. (NASDAQ:BTCY) a modern medical technology company delivering innovative, remote biometric monitoring solutions, today announced the successful completion of a $12 million non-convertible debt financing
Biotricity, a Leader in Remote Cardiac Health Monitoring Solutions, Issues Company Roadmap in 2021 Shareholder Letter
The Company believes that it is “well-positioned for 2022.”Letter highlights milestones, products roadmap, growth strategy and 2022 goalsREDWOOD CITY, CA / ACCESSWIRE / December 7, 2021 / Biotricity, Inc.
REDWOOD CITY, Calif., November 10, 2021–Biotricity Delivers Bioheart: A Groundbreaking Consumer Heart Monitor for Smartphones
* Company reports tenth consecutive quarter of triple-digit year-over-year revenue growth * Strongest balance sheet since inceptionREDWOOD CITY, CA / ACCESSWIRE / November 4, 2021 /Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced financial results for its 2022 fiscal year’s second quarter ended September 30, 2021.
Management to Host Conference Call and Live Webcast at 5pm ETREDWOOD CITY, CA / ACCESSWIRE / November 2, 2021 /Biotricity, Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will release its financial results for the second quarter ended September 30, 2021, on Thursday, November 4, 2021, after the close of the market.
Company Expects New Personal Medical Device Kit to be available to customer by early 2022
Underwritten Public Offering of Common Stock Resulted in Total Gross Proceeds of $16 Million
Company’s Momentum Continuing with Sales Growth, Recent Nasdaq listing and Successful Equity Raise
REDWOOD CITY, CA / ACCESSWIRE / August 26, 2021 / (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced the pricing of an underwritten public offering of 5,000,000…
REDWOOD CITY, CA / ACCESSWIRE / August 25, 2021 / (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it intends to offer shares of its common stock for…
REDWOOD CITY, CA / ACCESSWIRE / May 4, 2021 / , Inc. (OTCQB:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, is pleased to announce that it’s Biotres…
SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Waqaas Al-Siddiq, CEO of Biotricity Inc. (OTCQB: BTCY) (“the Company”), a modern medical technology company delivering…
REDWOOD CITY, CA / ACCESSWIRE / March 15, 2021 / (OTCQB:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, is pleased to announce that CEO Waqaas Al-Siddiq…
REDWOOD CITY, CA / ACCESSWIRE / February 11, 2021 / Inc. (OTCQB:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, is pleased to provide unaudited,…
Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will discuss the highlights of its financial results for the third quarter of…
Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it has completed a series of closings pursuant to which it sold an aggregate gross proceeds…
Bioheart comfortably and continuously monitors daily activities and provides advanced heart performance data in a user-friendly format
Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it made a 510(k) submission to the U.S. Food and Drug Administration (FDA), on December…
Dr. Waqaas Al-Siddiq, Phd
Chairman, CEO & Founder
Waqaas, the founder of Biotricity, is a serial entrepreneur, a former investment advisor and an expert in wireless communication technology. Academically, he was distinguished for his various innovative designs in digital, analog, embedded, and micro-electro-mechanical products. His work was published in various conferences such as IEEE and the National Communication Council.
Waqaas has held several high-level design positions in IBM, AMD, and Intel. His achievements have been numerous in both the technical and academic world. Coupled with this, Waqaas has vast experience in leading various groups through his board experience and executive roles within start-ups, mid-sized companies, and non-profits.
Waqaas has a dual Bachelor’s degree in Computer Engineering and Economics, a Master’s in Computer Engineering from Rochester Institute of Technology, and a Master’s in Business Administration from Henley Business School. He also holds a Doctorate in Business with a specialty in Transformative Innovations and Billion Dollar Markets.
Norman Betts, Phd
Independent Board Member
Norman sits on the Boards of Directors of the Bank of Canada, Tembec Inc., New Brunswick Power Corporation, 49 North Resources Inc., Adex Mining Inc., Tanzanian Royalty Exploration Inc. and the University of New Brunswick Pension Plan for Academic Employees.
Norman is an Associate Professor in the Faculty of Business Administration at the University of New Brunswick in Fredericton. He is accomplished in the field of accounting and finance, with a mix of academic, public, and private-sector experience. He is an expert in accounting regulations, and has extensive experience in audits, risk management, governance and oversight. He was a member of the New Brunswick Legislative Assembly from 1993 to 2003 and held three different cabinet posts, including Minister of Finance from 1999 to 2001. Prior to entering politics, Norman was Assistant Dean of the MBA Programme and an Associate Professor at the University of New Brunswick as well as a partner in the accounting firm Shannon, Betts & Buffett.
Norman received a PhD in Management with a concentration in accounting and finance from Queen’s University School of Business in 1992 and a Bachelor of Business Administration from the University of New Brunswick in 1978. He also holds a Fellow Chartered Accountant designation.
Independent Board Member
Dave has spent the past 22 years in a variety of positions in the medical device industry. He was appointed CEO of Sunshine Heart in October of 2009 and served as President and Chief Executive Officer through November 2015. Dave took Sunshine Heart Public on NASDAQ in 2012 and raised over $120M during his tenure. The Company achieved a number of clinical, regulatory and research and development milestones under his leadership. Prior to joining Sunshine Heart, he was President and CEO of Milksmart, Inc., a privately held company developing a unique stent-like agricultural technology that increases milking efficiencies, output and quality. From 2004-2008, Dave was Vice President of Global Marketing for Cardiac Surgery and Cardiology at St. Jude Medical, Inc. While at St. Jude, he developed the strategic pan for the newly formed interventional division, directed the launch of several new products and oversaw the acquisition and integration of Velocimed, a privately held company in the cardiovascular space.
From 1999-2004, Dave held executive management positions at privately held A-Med Systems, Inc., an emerging medical technology company that developed ventricular assist devices (pVADs) for acute heart failure. His roles included Vice President of Marketing and Sales, Chief Operating Officer and Chief Executive Officer. From 1995- 1999, Dave served as Product Manager for Angioplasty Balloons and Director of Intravascular Ultrasound at SCIMED Life Systems, a privately held company that was engaged in the development, manufacture and marketing of medical devices to treat cardiovascular disease. SCIMED was acquired by Boston Scientific Corporation and now operates as a subsidiary of Boston Scientific. Dave holds an M.B.A. in Marketing Management from Duquesne University and a B.S. in Commerce and Engineering from Drexel University.
Independent Board Member
Patricia has spent over 25 years in a variety of global sales and distribution positions in the medical device industry, focusing on the field of Electrophysiology. In 2015, she founded and is currently the Managing Director of PJM Medical Consultants, supporting medical device companies entering the international market with market entry and product commercialization strategies. From 2008 to 2015, Pat served as VP – International and General Manager for Atricure, Inc. She achieved significant sales, market development and clinical science milestones, while defining strategic plans and pursuing technology development and acquisitions. From 2001 to 2008, Pat worked with Stereotaxis, Inc. in numerous executive positions including Worldwide VP – Clinical Services and VP – International Sales and Marketing.
Prior to Stereotaxis, Pat worked with EP MedSystems as International Marketing Manager for defibrillation and diagnostic catheters. She began her career in the medical industry at Boston Scientific from 1992 to 1997 while serving in several positions, including Sales and International Product Manager for EPT. Pat has earned a Bachelor of Science Degree in Marketing from the University of Florida and a Bachelor of Science in Nursing degree from the University of North Florida.
Independent Board Member
Steve Salmon has expertise in business development transactions, market development, finance, technology, and capital market. His most recent experience was as a Venture Capitalist for Latterell Venture Partners, where he managed a number of portfolio companies. Prior to becoming a VC, Mr. Salmon was a founder of Ensure Medical and Integrated Vascular Systems, both of which were successfully exited through acquisition. He also served as the CEO of Revascular which was also acquired. Mr. Salmon brings to Biotricity his deep expertise in raising capital, facilitating growth, and driving long term value.
Chief Financial Officer
John has over 25 years of accounting, finance, and operations experience, having previously served as CFO of several public companies and a regulated financial institution. As CFO of Equitable Group, Mr. Ayanoglou raised over $130 million of regulatory capital in common, preferred, and debenture offerings over successive transactions, all during a period of extreme capital market turbulence, helping to successfully grow assets under administration from $6.1 billion to over $10 billion to facilitate Equitable Bank in becoming Canada’s ninth largest bank. He was also the CFO and Corporate Secretary of Xceed Mortgage Corporation, where he partnered with an entrepreneurial top team to grow the business through the successful implementation of warehouse financing lines and other securitization programs including public term securitizations of over $700 million.
John has extensive experience as a trusted business advisor working with management teams and boards on business acquisition and consolidation, risk mitigation and turnaround, to establish efficient, effective operations. He is a CA, CPA with a Bachelor of Commerce degree in Finance and Economics from the University of Toronto and his ICD.D designation from the Institute of Corporate Directors and the Rotman School of Business.
Chief Development Officer
Amir is a serial entrepreneur with over 20 years of experience in launching companies and producing innovative products, services, and solutions. Amir is sought after for his expertise in transforming R&D technologies into products based on market needs, commercializing products for volume production, and establishing global distribution channels across the world.
Prior to joining Biotricity, Amir served as CEO at AT Labs Inc., where his team pioneered the concept of wireless mobile thin clients to access secure enterprise applications through the cloud. The efficacy of the robust solutions resulted in customers from healthcare, government, enterprise, and retail sectors, most of which spanned thousands of locations across the United States. His experience in developing such novel technologies has put him at the forefront of companies that have grown in revenue from zero to over $160 million. In his own ventures, he has worked with many leading industrial and financial institutional funders including Jafo, Bay Partners, and JP Morgan with whom he has raised over $35 million.
Vice President, Engineering
Spencer is an expert in wireless communication and has worked with the United States Department of Defense. His academic career was highlighted by various innovative projects and designs. Spencer obtained his undergraduate degree while balancing a full-time job at Flightline Systems Ultra Electronics, a small defense contractor. His specialties are in the design and implementation of radio frequency, digital, analog, embedded software and PC software. Spencer also has experience in working with marketing, sales, and manufacturing teams in order to develop products for large-scale output. Spencer has a Bachelor’s degree in Computer Engineering from Rochester Institute of Technology.
Thomas C. Nelson
Nelson serves as the president of Share Our Strength, a national nonprofit that is ending childhood hunger in America. Prior to joining Share Our Strength in 2011, Nelson was chief operating officer for AARP, where he led the build-out of its state strategy in all 53 US states and territories. In addition to serving as an adjunct professor at Georgetown University’s McDonough School of Business, Nelson has a long history of service to civic organizations, including his current position on the board of directors of ProInspire. Other board positions include, the board of counselors for the Davis Gerontology School at the University of Southern California; the board of the Certified Financial Planner Board of Standards; and the board of Community Wealth Partners. Nelson holds a Ph.D. from the University of Southern California and an M.A. from Columbia University.
John Rother, JD
Mr. Rother is President and CEO of the National Coalition on Health Care, America’s oldest and most diverse group working to achieve comprehensive health system change. Prior to joining the Coalition in 2011, Rother worked at AARP for over 27 years as the Executive Vice President for Policy, Strategy, and International Affairs where he led the development of AARP’s policy positions and advocacy strategies. Under his leadership, AARP engaged in public policy research and analysis, public education, and advocacy on health and retirement issues at the federal, state and international levels. Rother wrote numerous articles and was a frequent speaker on health, retirement security, the federal budget, and the boomer generation.
Prior to that, Rother was Staff Director and Chief Counsel for the U.S. Senate Special Committee on Aging under the direction of Chairman John Heinz and served as Special Counsel for Labor and Health to U.S. Senator Jacob Javits. He has consistently been named as one of the most powerful people in Healthcare and in 2010 received the Robert Ball Award for Outstanding Achievements in Social Insurance from the National Academy of Social Insurance for “lifetime advocacy to strengthen Social Security and Medicare.”
Daniel Sands, MD, MPH
Dr. Sands is passionate about healthcare transformation, non-visit based care, collaboration in healthcare, and participatory medicine. He spent six years at Cisco, as chief medical informatics officer, where he provided both internal and external health IT leadership and helped key customers with business and clinical transformation using IT. Sands’ prior position was chief medical officer for Zix Corporation, a leader in secure e-mail and e-prescribing. Sands also spent 13 years at Beth Israel Deaconess Medical Center in Boston, where he developed and implemented numerous systems to improve clinical care delivery and patient engagement.
He has earned degrees from Brown University, Ohio State University and the Harvard School of Public Health, and trained at Boston City Hospital and Boston’s Beth Israel Hospital. Sands currently holds an academic appointment at Harvard Medical School and maintains a primary care practice in which he makes extensive use of health IT. He works as a consultant for a variety of innovative companies. Sands is the recipient of numerous health IT awards, has been elected to fellowship in both the American College of Physicians and the American College of Medical Informatics, and is a founder and co-chair of the board of the Society for Participatory Medicine. In 2009, he was recognized by HealthLeaders Magazine as one of “20 People Who Make Healthcare Better.”